Loading…

Development of Oral Controlled Release Tablet Formulations Based on Diltiazem-Carrageenan Complex

Diltiazem HCl and lambda carrageenan react in distilled water to give a slightly soluble interaction product. The aim of this work was to verify the possible employment of lambda carrageenan-diltiazem (DTZ) complex in controlled-release formulations. The influence of complex particle size, compressi...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical development and technology 2004, Vol.9 (2), p.155-162
Main Authors: Bonferoni, M. C., Rossi, S., Ferrari, F., Caramella, C.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c348t-17d21b68915bc9091902744a327618b13c49213f916a0c26e9f29b3fecf4e4e03
cites cdi_FETCH-LOGICAL-c348t-17d21b68915bc9091902744a327618b13c49213f916a0c26e9f29b3fecf4e4e03
container_end_page 162
container_issue 2
container_start_page 155
container_title Pharmaceutical development and technology
container_volume 9
creator Bonferoni, M. C.
Rossi, S.
Ferrari, F.
Caramella, C.
description Diltiazem HCl and lambda carrageenan react in distilled water to give a slightly soluble interaction product. The aim of this work was to verify the possible employment of lambda carrageenan-diltiazem (DTZ) complex in controlled-release formulations. The influence of complex particle size, compression force, pH of the dissolution medium, and tablet dimensions on drug release has been evaluated. The results confirm the suitability of the DTZ-carrageenan interaction product for controlled-release formulations. Good compaction properties allow tablets to slowly erode, with only the addition of the amount of hydroxypropyl methylcellulose (HPMC) necessary as a binding agent. The use of the finest sieve fraction results in the highest crushing strength values and in the slowest release rate, both in pH 1.2 and in pH 6.8. The force of compression does not affect the drug release for values over 16 kN. The release rate increases when the geometry of the tablet is varied so the surface volume ratio of the tablet is increased, suggesting a release mechanism involving surface dissolution erosion.
doi_str_mv 10.1081/PDT-120027428
format article
fullrecord <record><control><sourceid>proquest_infor</sourceid><recordid>TN_cdi_informahealthcare_journals_10_1081_PDT_120027428</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66639863</sourcerecordid><originalsourceid>FETCH-LOGICAL-c348t-17d21b68915bc9091902744a327618b13c49213f916a0c26e9f29b3fecf4e4e03</originalsourceid><addsrcrecordid>eNp1kMtv1DAQhyNERR9w5Ip8gVuoH0lsH2GXAlKlVmg5WxNnTFM59mInQPnr69Uujx568kj-5jczX1W9ZPQto4qdX683NeOUctlw9aQ6YVTLWqtOPt3VStSyaelxdZrzLaVMado-q45ZyylvZXNSwRp_oI_bCcNMoiNXCTxZxTCn6D0O5At6hIxkA73HmVzENC0e5jGGTN6Xj4HEQNajn0f4jVO9gpTgG2KAUFKmrcdfz6sjBz7ji8N7Vn29-LBZfaovrz5-Xr27rK1o1FwzOXDWd0qztreaaqZ3JzUguOyY6pmwjeZMOM06oJZ3qB3XvXBoXYMNUnFWvdnnblP8vmCezTRmi95DwLhk03WdKF5EAes9aFPMOaEz2zROkO4Mo2bn1BSn5q_Twr86BC_9hMM_-iCxAK8PAGQL3iUIdsz_cVLqTu0Gqz03Blc8ws-Y_GBmuPMx_WkSj-0gH7TeIPj5xkJCcxuXFIrYR7a_B35Hor8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66639863</pqid></control><display><type>article</type><title>Development of Oral Controlled Release Tablet Formulations Based on Diltiazem-Carrageenan Complex</title><source>EBSCOhost Business Source Ultimate</source><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Bonferoni, M. C. ; Rossi, S. ; Ferrari, F. ; Caramella, C.</creator><creatorcontrib>Bonferoni, M. C. ; Rossi, S. ; Ferrari, F. ; Caramella, C.</creatorcontrib><description>Diltiazem HCl and lambda carrageenan react in distilled water to give a slightly soluble interaction product. The aim of this work was to verify the possible employment of lambda carrageenan-diltiazem (DTZ) complex in controlled-release formulations. The influence of complex particle size, compression force, pH of the dissolution medium, and tablet dimensions on drug release has been evaluated. The results confirm the suitability of the DTZ-carrageenan interaction product for controlled-release formulations. Good compaction properties allow tablets to slowly erode, with only the addition of the amount of hydroxypropyl methylcellulose (HPMC) necessary as a binding agent. The use of the finest sieve fraction results in the highest crushing strength values and in the slowest release rate, both in pH 1.2 and in pH 6.8. The force of compression does not affect the drug release for values over 16 kN. The release rate increases when the geometry of the tablet is varied so the surface volume ratio of the tablet is increased, suggesting a release mechanism involving surface dissolution erosion.</description><identifier>ISSN: 1083-7450</identifier><identifier>EISSN: 1097-9867</identifier><identifier>DOI: 10.1081/PDT-120027428</identifier><identifier>PMID: 15202574</identifier><language>eng</language><publisher>New York, NY: Informa UK Ltd</publisher><subject>Administration, Oral ; Biological and medical sciences ; Carrageenan - chemistry ; Compressive Strength ; Controlled release ; Delayed-Action Preparations ; Diltiazem - administration &amp; dosage ; Diltiazem - chemistry ; Diltiazem HCl ; Drug Compounding - methods ; Drug-polymer complex ; Excipients - chemistry ; General pharmacology ; Hydrogen-Ion Concentration ; Lambda carrageenan ; Medical sciences ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Solubility ; Tablets ; Time Factors</subject><ispartof>Pharmaceutical development and technology, 2004, Vol.9 (2), p.155-162</ispartof><rights>2004 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2004</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c348t-17d21b68915bc9091902744a327618b13c49213f916a0c26e9f29b3fecf4e4e03</citedby><cites>FETCH-LOGICAL-c348t-17d21b68915bc9091902744a327618b13c49213f916a0c26e9f29b3fecf4e4e03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15779683$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15202574$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bonferoni, M. C.</creatorcontrib><creatorcontrib>Rossi, S.</creatorcontrib><creatorcontrib>Ferrari, F.</creatorcontrib><creatorcontrib>Caramella, C.</creatorcontrib><title>Development of Oral Controlled Release Tablet Formulations Based on Diltiazem-Carrageenan Complex</title><title>Pharmaceutical development and technology</title><addtitle>Pharm Dev Technol</addtitle><description>Diltiazem HCl and lambda carrageenan react in distilled water to give a slightly soluble interaction product. The aim of this work was to verify the possible employment of lambda carrageenan-diltiazem (DTZ) complex in controlled-release formulations. The influence of complex particle size, compression force, pH of the dissolution medium, and tablet dimensions on drug release has been evaluated. The results confirm the suitability of the DTZ-carrageenan interaction product for controlled-release formulations. Good compaction properties allow tablets to slowly erode, with only the addition of the amount of hydroxypropyl methylcellulose (HPMC) necessary as a binding agent. The use of the finest sieve fraction results in the highest crushing strength values and in the slowest release rate, both in pH 1.2 and in pH 6.8. The force of compression does not affect the drug release for values over 16 kN. The release rate increases when the geometry of the tablet is varied so the surface volume ratio of the tablet is increased, suggesting a release mechanism involving surface dissolution erosion.</description><subject>Administration, Oral</subject><subject>Biological and medical sciences</subject><subject>Carrageenan - chemistry</subject><subject>Compressive Strength</subject><subject>Controlled release</subject><subject>Delayed-Action Preparations</subject><subject>Diltiazem - administration &amp; dosage</subject><subject>Diltiazem - chemistry</subject><subject>Diltiazem HCl</subject><subject>Drug Compounding - methods</subject><subject>Drug-polymer complex</subject><subject>Excipients - chemistry</subject><subject>General pharmacology</subject><subject>Hydrogen-Ion Concentration</subject><subject>Lambda carrageenan</subject><subject>Medical sciences</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Solubility</subject><subject>Tablets</subject><subject>Time Factors</subject><issn>1083-7450</issn><issn>1097-9867</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNp1kMtv1DAQhyNERR9w5Ip8gVuoH0lsH2GXAlKlVmg5WxNnTFM59mInQPnr69Uujx568kj-5jczX1W9ZPQto4qdX683NeOUctlw9aQ6YVTLWqtOPt3VStSyaelxdZrzLaVMado-q45ZyylvZXNSwRp_oI_bCcNMoiNXCTxZxTCn6D0O5At6hIxkA73HmVzENC0e5jGGTN6Xj4HEQNajn0f4jVO9gpTgG2KAUFKmrcdfz6sjBz7ji8N7Vn29-LBZfaovrz5-Xr27rK1o1FwzOXDWd0qztreaaqZ3JzUguOyY6pmwjeZMOM06oJZ3qB3XvXBoXYMNUnFWvdnnblP8vmCezTRmi95DwLhk03WdKF5EAes9aFPMOaEz2zROkO4Mo2bn1BSn5q_Twr86BC_9hMM_-iCxAK8PAGQL3iUIdsz_cVLqTu0Gqz03Blc8ws-Y_GBmuPMx_WkSj-0gH7TeIPj5xkJCcxuXFIrYR7a_B35Hor8</recordid><startdate>2004</startdate><enddate>2004</enddate><creator>Bonferoni, M. C.</creator><creator>Rossi, S.</creator><creator>Ferrari, F.</creator><creator>Caramella, C.</creator><general>Informa UK Ltd</general><general>Taylor &amp; Francis</general><general>Informa Healthcare</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2004</creationdate><title>Development of Oral Controlled Release Tablet Formulations Based on Diltiazem-Carrageenan Complex</title><author>Bonferoni, M. C. ; Rossi, S. ; Ferrari, F. ; Caramella, C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c348t-17d21b68915bc9091902744a327618b13c49213f916a0c26e9f29b3fecf4e4e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Administration, Oral</topic><topic>Biological and medical sciences</topic><topic>Carrageenan - chemistry</topic><topic>Compressive Strength</topic><topic>Controlled release</topic><topic>Delayed-Action Preparations</topic><topic>Diltiazem - administration &amp; dosage</topic><topic>Diltiazem - chemistry</topic><topic>Diltiazem HCl</topic><topic>Drug Compounding - methods</topic><topic>Drug-polymer complex</topic><topic>Excipients - chemistry</topic><topic>General pharmacology</topic><topic>Hydrogen-Ion Concentration</topic><topic>Lambda carrageenan</topic><topic>Medical sciences</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Solubility</topic><topic>Tablets</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bonferoni, M. C.</creatorcontrib><creatorcontrib>Rossi, S.</creatorcontrib><creatorcontrib>Ferrari, F.</creatorcontrib><creatorcontrib>Caramella, C.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmaceutical development and technology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bonferoni, M. C.</au><au>Rossi, S.</au><au>Ferrari, F.</au><au>Caramella, C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of Oral Controlled Release Tablet Formulations Based on Diltiazem-Carrageenan Complex</atitle><jtitle>Pharmaceutical development and technology</jtitle><addtitle>Pharm Dev Technol</addtitle><date>2004</date><risdate>2004</risdate><volume>9</volume><issue>2</issue><spage>155</spage><epage>162</epage><pages>155-162</pages><issn>1083-7450</issn><eissn>1097-9867</eissn><abstract>Diltiazem HCl and lambda carrageenan react in distilled water to give a slightly soluble interaction product. The aim of this work was to verify the possible employment of lambda carrageenan-diltiazem (DTZ) complex in controlled-release formulations. The influence of complex particle size, compression force, pH of the dissolution medium, and tablet dimensions on drug release has been evaluated. The results confirm the suitability of the DTZ-carrageenan interaction product for controlled-release formulations. Good compaction properties allow tablets to slowly erode, with only the addition of the amount of hydroxypropyl methylcellulose (HPMC) necessary as a binding agent. The use of the finest sieve fraction results in the highest crushing strength values and in the slowest release rate, both in pH 1.2 and in pH 6.8. The force of compression does not affect the drug release for values over 16 kN. The release rate increases when the geometry of the tablet is varied so the surface volume ratio of the tablet is increased, suggesting a release mechanism involving surface dissolution erosion.</abstract><cop>New York, NY</cop><pub>Informa UK Ltd</pub><pmid>15202574</pmid><doi>10.1081/PDT-120027428</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1083-7450
ispartof Pharmaceutical development and technology, 2004, Vol.9 (2), p.155-162
issn 1083-7450
1097-9867
language eng
recordid cdi_informahealthcare_journals_10_1081_PDT_120027428
source EBSCOhost Business Source Ultimate; Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
subjects Administration, Oral
Biological and medical sciences
Carrageenan - chemistry
Compressive Strength
Controlled release
Delayed-Action Preparations
Diltiazem - administration & dosage
Diltiazem - chemistry
Diltiazem HCl
Drug Compounding - methods
Drug-polymer complex
Excipients - chemistry
General pharmacology
Hydrogen-Ion Concentration
Lambda carrageenan
Medical sciences
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Solubility
Tablets
Time Factors
title Development of Oral Controlled Release Tablet Formulations Based on Diltiazem-Carrageenan Complex
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T02%3A16%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20Oral%20Controlled%20Release%20Tablet%20Formulations%20Based%20on%20Diltiazem-Carrageenan%20Complex&rft.jtitle=Pharmaceutical%20development%20and%20technology&rft.au=Bonferoni,%20M.%20C.&rft.date=2004&rft.volume=9&rft.issue=2&rft.spage=155&rft.epage=162&rft.pages=155-162&rft.issn=1083-7450&rft.eissn=1097-9867&rft_id=info:doi/10.1081/PDT-120027428&rft_dat=%3Cproquest_infor%3E66639863%3C/proquest_infor%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c348t-17d21b68915bc9091902744a327618b13c49213f916a0c26e9f29b3fecf4e4e03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=66639863&rft_id=info:pmid/15202574&rfr_iscdi=true